TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34588274

Group type: EXPERIMENTAL
Intervention: Physical function assessment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Severe fatigue assessment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) independence
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cognitive impairment assessment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mental health assessment (depression, anxiety, PTSD)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Health-related quality of life
Number of subjects: 114
Study: 34588763

Group type: EXPERIMENTAL
Intervention: wDDART (web-based Democritus Digital Acuity Reading Test)
Number of subjects: 100

Group type: COMPARATOR
Intervention: DDART (conventional Windows-based reading test)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: wDDART
Number of subjects: 100
Study: 34588990

Group type: EXPERIMENTAL
Intervention: Propofol induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34589194

Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI) with Nuwiq
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ITI with emicizumab prophylaxis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study: 34589419

Group type: EXPERIMENTAL
Intervention: Lobaplatin plus docetaxel
Number of subjects: 458

Group type: COMPARATOR
Intervention: Cisplatin plus docetaxel
Number of subjects: 458
Study: 34589902

Group type: EXPERIMENTAL
Intervention: escitalopram/memantine (ESC/MEM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: escitalopram/placebo (ESC/PBO)
Number of subjects: 90
Study: 34589918

Group type: EXPERIMENTAL
Intervention: Simplified Prognostic Score (SPS) based on clinical and biological variables including TNM stage, performance status, liver metastases, and neutrophil-to-lymphocyte ratio.
Number of subjects: 401

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 401
Study: 34589965

Group type: EXPERIMENTAL
Intervention: Pegargiminase (ADI-PEG 20) plus Pemetrexed and Cisplatin (ADIPemCis)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pegargiminase (ADI-PEG 20)
Number of subjects: 32
Study: 34589978

Group type: EXPERIMENTAL
Intervention: Telephone-based smoking cessation counseling intervention
Number of subjects: 337

Group type: COMPARATOR
Intervention: Usual care (information pamphlet)
Number of subjects: 337
Study: 34589984

Group type: EXPERIMENTAL
Intervention: Rociletinib 500 mg twice daily
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Rociletinib 625 mg twice daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Rociletinib (500 mg and 625 mg twice daily) in T790M-positive patients
Number of subjects: 149
Study: 34590023

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus Erlotinib (RAM + ERL)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo plus Erlotinib (PL + ERL)
Number of subjects: 211
Study: 34590034

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg, flat dose on day 1, every 3 weeks for 2 years) plus Amrubicin (40 mg/m2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Amrubicin
Number of subjects: 25
Study: 34590048

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg, 10 mg/kg, or 200 mg every 3 weeks or 10 mg/kg every 2 weeks)
Number of subjects: 3170

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 3170

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 3170
Study: 34590052

Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d (part A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d (part B)
Number of subjects: 32
Study: 34590303

Group type: EXPERIMENTAL
Intervention: Earlier corticosteroid and tocilizumab use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34590307

Group type: EXPERIMENTAL
Intervention: Autologous blood or PRP injection
Number of subjects: 2337
Study: 34590610

Group type: EXPERIMENTAL
Intervention: Gamma Secretase Inhibitor AL101
Number of subjects: 2
Study: 34591023

Group type: EXPERIMENTAL
Intervention: Smartwatch-enabled remote monitoring with SmokeBeat program for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: No remote monitoring for 12 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pay-to-wear program for 4 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pay-to-quit program for 4 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pay-to-quit program with higher incentives for 3 weeks
Number of subjects: 39
Study: 34591024

Group type: EXPERIMENTAL
Intervention: Deep-learning algorithms (CNN)
Number of subjects: 18813

Group type: EXPERIMENTAL
Intervention: Deep-learning algorithms (RNN)
Number of subjects: 18813

Group type: COMPARATOR
Intervention: Logistic regression algorithm
Number of subjects: 18813

Group type: EXPERIMENTAL
Intervention: STEP-OP (weighted average of deep-learning models)
Number of subjects: 18813
Study: 34591030

Group type: EXPERIMENTAL
Intervention: Medical Companion smartphone application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian network (BN) algorithm
Number of subjects: 0
Study: 34591807

Group type: EXPERIMENTAL
Intervention: Preoperative EEG with lower spectral edge frequency (SEF)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Preoperative EEG with lower γ-band power
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Postinduction absolute α-band power
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: SEF ratio from preoperative to postinduction state
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Preoperative SEF, preoperative γ-band power, and SEF ratio
Number of subjects: 237
Study: 34591989

Group type: EXPERIMENTAL
Intervention: Treated patients with CLL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients with CLL
Number of subjects: 0
Study: 34592057

Group type: EXPERIMENTAL
Intervention: BACE1 inhibitors
Number of subjects: 3536

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (NB, kNN, SVM, RF, XGB)
Number of subjects: 3536
Study: 34592319

Group type: EXPERIMENTAL
Intervention: PRISm (Preserved Ratio Impaired Spirometry)
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: PRISm
Number of subjects: 1775
Study: 34592755

Group type: EXPERIMENTAL
Intervention: TCRαβ/CD19-depleted haploidentical HSCT from an HLA-partially matched relative
Number of subjects: 70
Study: 34592798

Group type: EXPERIMENTAL
Intervention: Aripiprazole Once Monthly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily Oral Atypical Antipsychotic Treatment
Number of subjects: 0
Study: 34592998

Group type: EXPERIMENTAL
Intervention: Hospitalization for any cause
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Respiratory-related hospitalization
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Hospitalization with ventilatory support
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Mortality during hospitalization or within 90 days of discharge
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Mortality associated with respiratory hospitalization or hospitalization with ventilatory support
Number of subjects: 1002
Study: 34593001

Group type: EXPERIMENTAL
Intervention: NEWS2 ≥ 5
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: NEWS2 ≥ 7
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tools ≥ 2
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: NEWS2
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tools
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: RETTS ≥ orange
Number of subjects: 323
Study: 34593173

Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL 4.0 GCS)
Number of subjects: 329
Study: 34593270

Group type: EXPERIMENTAL
Intervention: Fractional (1/5th dose-volume) RTS,S/AS01
Number of subjects: 49
Study: 34593491

Group type: EXPERIMENTAL
Intervention: MRI scan and PSA blood test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care tests for prostate cancer assessment (including multiparametric MRI)
Number of subjects: 0
Study: 34593490

Group type: EXPERIMENTAL
Intervention: MLR-DBS (mesencephalic locomotor region deep brain stimulation) during locomotion training
Number of subjects: 1
Study: 34593497

Group type: EXPERIMENTAL
Intervention: Additional diagnostic tests including infection markers, POC urine flow cytometry, POC analysis of sputum, POC and specialist ultrasound, and ULDCT
Number of subjects: 1000
Study: 34593530

Group type: EXPERIMENTAL
Intervention: Newly trained classifiers
Number of subjects: 0
Study: 34593600

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for acute large vessel occlusion (LVO)
Number of subjects: 1557
Study: 34593959

Group type: EXPERIMENTAL
Intervention: High-Resolution Melting (HRM) assays to genotype Pfs47 SNPs 707 and 725
Number of subjects: 4971

Group type: COMPARATOR
Intervention: Pfs47 sequences from Africa, Asia, and the New World
Number of subjects: 4971

Group type: EXPERIMENTAL
Intervention: Pfs47 sequences from Papua New Guinea
Number of subjects: 4971
Study: 34594036

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (first dose)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (second dose)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (third dose)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control cohort (participants without cancer)
Number of subjects: 53
Study: 34595223

Group type: EXPERIMENTAL
Intervention: Epicardial transplantation of autologous cardiac micrografts during coronary artery bypass surgery
Number of subjects: 0
Study: 34595805

Group type: EXPERIMENTAL
Intervention: Positive ANA testing in patients with gastroparesis
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Positive ANA in idiopathic gastroparesis
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Positive ANA in T1DM gastroparesis
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Positive ANA in T2DM gastroparesis
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Positive ANA in postfundoplication gastroparesis
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: ANA titer levels in idiopathic gastroparesis
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Association of ANA positivity with gender and ethnicity
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Association of ANA positivity with comorbidities
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Impact of ANA positivity on GCSI
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Relation of ANA positivity to gastric emptying
Number of subjects: 893
Study: 34595830

Group type: EXPERIMENTAL
Intervention: Postpartum dietary restrictions
Number of subjects: 682

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 682
Study: 34596039

Group type: EXPERIMENTAL
Intervention: Variable negative external pressure (vNEP) therapy
Number of subjects: 28
Study: 34596097

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling training (3 sessions/week)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling training (2-4 sessions/week)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling training
Number of subjects: 1
Study: 34596223

Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Number of subjects: 45542

Group type: COMPARATOR
Intervention: Non-Remdesivir (non-RDV)
Number of subjects: 45542

Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for NSO
Number of subjects: 45542

Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for LFO
Number of subjects: 45542

Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for IMV/ECMO
Number of subjects: 45542

Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for HFO/NIV
Number of subjects: 45542
Study: 34596445

Group type: EXPERIMENTAL
Intervention: Surprise Question responses
Number of subjects: 250
Study: 34596770

Group type: EXPERIMENTAL
Intervention: T-Scan digital occlusal analysis system
Number of subjects: 40

Group type: COMPARATOR
Intervention: CEREC Omnicam system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T-Scan
Number of subjects: 40

Group type: COMPARATOR
Intervention: CEREC Omnicam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T-Scan and CEREC Omnicam
Number of subjects: 40
Study: 34596937

Group type: EXPERIMENTAL
Intervention: MA (intensified induction chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytarabine (1600 mg/m2) from AAML0531 trial
Number of subjects: 0
Study: 34597119

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1 g daily plus prednisone 10 mg and luteinizing hormone-releasing hormone agonist until progression or unacceptable toxicities
Number of subjects: 24
Study: 34597411

Group type: EXPERIMENTAL
Intervention: Event Notification Service (ENS) alerts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no ENS alerts)
Number of subjects: 0
Study: 34597414

Group type: EXPERIMENTAL
Intervention: Extensive tests including computed tomography (CT) scanning
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Standard testing plus positron emission tomography (PET)/CT scanning
Number of subjects: 1644
Study: 34598099

Group type: EXPERIMENTAL
Intervention: NightWatch wearable seizure detection device used for two months at home.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: NightWatch wearable seizure detection device
Number of subjects: 23
Study: 34598702

Group type: EXPERIMENTAL
Intervention: Evidence-based diabetes shared medical appointment intervention
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Study team members' training on PRECIS-2 scoring
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Protocol refinements to achieve pragmatism
Number of subjects: 22
Study: 34598945

Group type: EXPERIMENTAL
Intervention: MK-4830 monotherapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MK-4830 in combination with pembrolizumab
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MK-4830 monotherapy and combination therapy
Number of subjects: 84
Study: 34599020

Group type: EXPERIMENTAL
Intervention: PD-L1-targeted CD47 bispecific antibody
Number of subjects: 0
Study: 34599023

Group type: EXPERIMENTAL
Intervention: Sitravatinib 120 mg daily from day 1 up to 48 hours pre-surgery and nivolumab 240 mg on day 15.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitravatinib alone (1A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitravatinib-nivolumab (1B)
Number of subjects: 10
Study: 34599042

Group type: EXPERIMENTAL
Intervention: Second wave antibodies treatment (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 34599144

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake and gut microbiota analysis
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) treatment
Number of subjects: 27
Study: 34599228

Group type: EXPERIMENTAL
Intervention: CYP2A6 (intronic) variant rs56113850 in EA females
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: CYP2A6 (intronic) variant rs56113850 in EA males
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: CYP2A6 (~ 16 kb 3') variant rs11878604 in AA females
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: CYP2A6 (~ 7 kb 3') variant rs3865454 in AA males
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: TMEM132C (~ 1 Mb 5') variant rs12425845 in AA females
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: SLC17A2 (~ 8 kb 5') variant rs9379805 in AA males
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: ZNF469 (~ 92 kb 5') variant rs77368288 in AA males
Number of subjects: 1785
Study: 34599726

Group type: EXPERIMENTAL
Intervention: Ixazomib plus lenalidomide and dexamethasone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo plus lenalidomide and dexamethasone
Number of subjects: 34
Study: 34600119

Group type: EXPERIMENTAL
Intervention: Composite of major adverse clinical events during hospitalization (including mortality, mechanical ventilation, high-flow nasal oxygen therapy, prone positioning, sepsis, systemic inflammatory response syndrome, and embolic events)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Respiratory insufficiency on admission
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Cough on admission
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Mean age of patients in combined event group
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Mean age of patients in non-combined event group
Number of subjects: 773
Study: 34600310

Group type: EXPERIMENTAL
Intervention: Patients with psychiatric conditions
Number of subjects: 230

Group type: COMPARATOR
Intervention: Healthy control group (n = 230, age = 39.4 ± 14.9 years, 80% female)
Number of subjects: 230
Study: 34600468

Group type: EXPERIMENTAL
Intervention: Erenumab every 28 days for a period of 12 months
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 75
Study: 34600524

Group type: EXPERIMENTAL
Intervention: Cultural context factors (religiosity and social support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Religiosity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empowerment
Number of subjects: 0
Study: 34600527

Group type: EXPERIMENTAL
Intervention: DPP-GLB intervention
Number of subjects: 240
Study: 34600543

Group type: EXPERIMENTAL
Intervention: Traditional Chinese version of the Resilience Scale for Children (RS-10)
Number of subjects: 186
Study: 34600582

Group type: EXPERIMENTAL
Intervention: Implanted perforated lacrimal punctal plugs
Number of subjects: 29
Study: 34600820

Group type: EXPERIMENTAL
Intervention: rhHNS IT (10 mg, 45 mg, 90 mg)
Number of subjects: 12
Study: 34600872

Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Number of subjects: 0
Study: 34600873

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2008
Study: 34601043

Group type: EXPERIMENTAL
Intervention: Percutaneous renal transluminal angioplasty (PTRA) guided by trans-stenotic pressure measurements
Number of subjects: 24

Group type: COMPARATOR
Intervention: Visual angiographic parameters
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pressure measurements made by a 4F catheter
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PTRA
Number of subjects: 24
Study: 34601071

Group type: EXPERIMENTAL
Intervention: Somapacitan (tritium-labelled)
Number of subjects: 0
Study: 34601202

Group type: EXPERIMENTAL
Intervention: Ig20Gly 800-mg/kg total loading dose (1-week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ig20Gly 400-mg/kg total loading dose (1-week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ig20Gly 800-mg/kg total loading dose (2-week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ig20Gly 100-mg/kg weekly maintenance dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ig20Gly 200-mg/kg weekly maintenance dose
Number of subjects: 0
Study: 34601579

Group type: EXPERIMENTAL
Intervention: Cold season in South Africa
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Hot season in South Africa
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Cold season in Tanzania
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Hot season in Tanzania
Number of subjects: 668
Study: 34601639

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HG) assessment
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: MRC score, MIP, PCEF assessments
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Handgrip strength correlation with MRC score
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Hospital length of stay
Number of subjects: 233
Study: 34601646

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation for COVID-19
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: SAPS3 score
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Neutrophils to lymphocytes ratio
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Failed attempt of noninvasive positive pressure ventilation prior to intubation
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination strategy during ICU stay
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Low dosage of corticosteroids (methylprednisolone 1 mg/kg)
Number of subjects: 868
Study: 34601959

Group type: EXPERIMENTAL
Intervention: Different rest period durations prior to blood pressure measurement
Number of subjects: 0
Study: 34601970

Group type: EXPERIMENTAL
Intervention: Serum potassium management (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 34602290

Group type: EXPERIMENTAL
Intervention: Rucaparib treatment
Number of subjects: 545
Study: 34602995

Group type: EXPERIMENTAL
Intervention: Walking (WALK)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Seated social interactions (SOCIAL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Simple resistance activities (SRA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All conditions (WALK, SOCIAL, SRA)
Number of subjects: 13
Study: 34603507

Group type: EXPERIMENTAL
Intervention: Q6W dosing of natalizumab
Number of subjects: 438

Group type: COMPARATOR
Intervention: Q4W dosing of natalizumab
Number of subjects: 438
Study: 34603539

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion dysregulation (ED)
Number of subjects: 0
Study: 34604072

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg IV every 4 weeks for up to 1 year
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 37